Moderna and Merck’s mRNA Vaccine Shows Promise Against Melanoma: How Markets Will React?

The new mRNA vaccine developed by Moderna and Merck, when combined with Keytruda, reduced the risk of melanoma recurrence by 50% in a late-stage trial involving over 1,100 patients. The vaccine targets cancer cells' DNA, activating the immune system and significantly lowering the risk of cancer recurrence. This breakthrough could be a turning point for both Moderna (MRNA) and Merck (MRK), with shares of Moderna rising by 8% and Merck by 5%. The results suggest significant potential for mRNA-based treatments in cancer therapy, with FDA approval applications ongoing. Moderna is targeting $2.5 billion in revenue for 2025, while Merck had projected $1.5 billion for 2024.

This development could mark a turning point for Moderna and Merck. Moderna had projected $1.2 billion in revenue for 2024, but the results lifted its shares by 8%. Merck saw a 5% increase. The findings highlight the potential of mRNA-based therapies in cancer treatment, with FDA approvals still pending.